

22 January 2026

India | Equity Research | Results Update

Dr Reddy's Laboratories

Pharma

Near-term cliff makes risk-reward favourable

Dr. Reddy's Laboratories' (DRL) Q3FY26 reported performance was dragged by lower sales in the US (-16% YoY), though supported by forex gains and solid traction in Europe (~20%) and India (~19%). One-time provision of INR 1.17bn (130bps) pertaining to labour law code impacted margins; gross and EBITDA margins shrank by 455bps and 445bps YoY, respectively, on lower sales of Revlimid. Recent M&A and pipeline of niche opportunities like generic semaglutide and abatacept biosimilar may help DRL overcome the impact of loss of gRevlimid exclusivity in FY28. We lower FY27E EPS by ~1% to factor in slightly lower margins, though maintain our FY28E EPS. The stock is currently trading at attractive valuations of 2x FY28E P/B and 17.4x FY28E EPS. Upgrade to **ADD**; raise TP to INR 1,300 as we roll forward to FY28E EPS (20x P/E).

Barring one-offs, performance was in line with expectation

DRL's Q3FY26 revenue grew 4.4% YoY (-0.9% QoQ) to INR 87.3bn (I-Sec: INR 87.9bn) led by Europe and India. Provisions worth INR 1.17bn pertaining to new labour law code in India impacted gross margin and EBITDA margin by 50bps and 130bps, respectively. Adj. gross margin contracted ~455bps YoY (-54bps QoQ) to 54.1% due to lower sales of gRevlimid. Adj. R&D cost declined 10% YoY to INR 6.0bn and stood at 6.8% of sales vs. 8.0% in Q3FY25. Adj. EBITDA fell 12.5% YoY at INR 20.1bn (I-Sec: INR 19.9bn). Margin contracted 445bps YoY (-112bps QoQ) to 23.1%. Adj. PAT stood at INR 13.2bn, down 6.5% YoY (I-Sec: INR 12.6bn) due to weak margins.

Recent M&A, FX gains offset the dent of lower gRevlimid sales in US

US sales fell 15.7% YoY (-9.4% QoQ) to USD 338mn mainly due to lower sales of gRevlimid and pricing pressure in base portfolio. Management anticipates single-digit growth in base portfolio US led by new generic and biosimilar launches. We expect US sales of DRL to drop to USD 1.5bn by FY28E due to loss of exclusivity in gRevlimid from Q4FY26. India business grew 19.1% YoY to INR 16bn aided by growth in the innovation portfolio (10-15% of India sales), price increases and M&A. We expect India business to register 11.5% CAGR over FY25–28E. Europe sales grew 19.7% YoY to INR 14.5bn led by consolidation of NRT portfolio (85% done so far), new generic launches and forex gains. Russia sales grew 51.4% YoY (+21.1% QoQ) to INR 10.6bn. CIS revenue was flat YoY at INR 2.4bn. RoW business grew 20.2% YoY (+9.2% QoQ) at INR 6.0bn. PSAI revenue declined 2.5% YoY to INR 8.0bn.

Financial Summary

Y/E March (INR mn)	FY25A	FY26E	FY27E	FY28E
Net Revenue	3,25,535	3,47,745	3,54,215	3,95,248
EBITDA	87,232	83,621	79,354	93,070
EBITDA Margin (%)	26.8	24.0	22.4	23.5
Net Profit	58,564	55,143	46,490	55,558
EPS (INR)	70.2	66.1	55.7	66.6
EPS % Chg YoY	5.2	(5.9)	(15.7)	19.5
P/E (x)	17.1	17.8	20.8	17.4
EV/EBITDA (x)	12.0	11.8	12.0	9.9
RoCE (%)	16.5	13.0	10.0	11.0
RoE (%)	18.9	15.2	11.4	12.3

Abdulkader Puranwalaabdulkader.puranwala@icicisecurities.com
+91 22 6807 7339**Nisha Shetty**

nisha.shetty@icicisecurities.com

Darshil Jain

darshil.jain@icicisecurities.com

Market Data

Market Cap (INR)	966bn
Market Cap (USD)	10,533mn
Bloomberg Code	DRRD IN
Reuters Code	REDY.BO
52-week Range (INR)	1,380 / 1,020
Free Float (%)	73.0
ADTV-3M (mn) (USD)	23.7

Price Performance (%)	3m	6m	12m
Absolute	(10.2)	(8.1)	(10.2)
Relative to Sensex	(7.2)	(7.8)	(18.2)

ESG Score	2024	2025	Change
ESG score	74.9	73.1	(1.8)
Environment	72.3	76.5	4.2
Social	61.1	54.1	(7.0)
Governance	89.5	89.7	0.2

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: SES ESG, I-sec research

Earnings Revisions (%)	FY27E	FY28E
Revenue	(1.3)	(1.0)
EBITDA	0.7	1.0
EPS	(0.7)	0.1

Previous Reports

26-10-2025: [Q2FY26 results review](#)24-07-2025: [Q1FY26 results review](#)

Valuation and risks

Starting Q4FY26, generic companies including Dr Reddy's will no longer be bonded for market share in gRevlimid by the agreement with innovator. DRL has 71 pending ANDAs including 21 FTF opportunities in the pipeline which should help it offset base price erosion and boost single digit growth for base business (excluding gRevlimid). Its aim to completely integrate NRT portfolio by the end of CY26 along with the recent M&A in India could boost double-digit growth in markets outside the US. DRL further aims to scale up its consumer brand sales to USD 1bn (including USD 300mn from NRT) through M&As and growth in the existing business.

The company has booked GLP-1 fill finish capacity of 12mn pens for CY26 with a CMO and aims to enter Canada in next 1-4 months, India in Mar'26 and Brazil by Jul'26. Besides, it is on track to launch abatacept biosimilar in the US in next 12-15 months and in Europe (USD 2bn market) by Jul'27. Additionally, DRL is working on CRLs for denosumab and rituximab biosimilars and expects a resolution in the near term.

While FY27 could be a year of consolidation, we believe timely launch of generic Semaglutide across markets and abatacept biosimilar in the US and Europe could boost FY28E earnings by ~20%. Over FY26-28E, we expect DRL's EBITDA to grow at ~5% while PAT is likely to be flat (adj for gRevlimid PAT CAGR at 13%). DRL trades at valuations of 20.8x FY27E and 17.4x FY28E earnings and EV/EBITDA multiples of 12.0x FY27E and 9.9x FY28E; current valuations adequately factor in the hit to earnings due to loss of exclusivity in gRevlimid in the US. We upgrade DRL to **ADD** (from **Hold**) with a higher target price of INR 1,300 (INR 1,250 earlier), valuing the business at 20x FY28E earnings (22x FY27E earlier).

Key downside risks: Delay in launching new products, regulatory hurdles and higher-than-anticipated competition in semaglutide.

Q3FY26 conference call highlights

US

- Received a form 483 with five observations post a GMP and a PAI conducted by the USFDA at FTO-SEZ PU-01 (formulations facility) in Srikakulam, Andhra Pradesh. The company has filed its reply with the USFDA within the stipulated timeline.
- US sales stood at USD 338mn, declined by 14.5% due to lower Lenalidomide sales and higher price erosion in certain key products.
- During the quarter, it launched six new products and a total of 18 new products were launched during 9MFY26.
- Filed four new ANDAs with the USFDA during the quarter and a total of 10 for 9MFY26.
- At the end of Dec'25, it had 73 filings pending approval with the USFDA including 71 ANDAs (43 are Paragraph IV, and 21 FTF products) and two NDAs.
- The company will continue to sell gRevlimid in Q4FY26; however, it will no longer be bound by the agreement with the innovator.

India

- Growth in India was driven by revenues from innovation portfolio, new brand launches, price increases, higher volumes and recently acquired Stugeron portfolio.
- Organic growth stood at 17%.

- Launched two new brands in Q3FY26, taking the total to 18 for 9MFY26.
- Innovation portfolio accounts for 10-15% of India sales.
- India growth was not boosted by any spillover of sales from Q2FY26 due to the implementation of GST rate cut.

Europe

- It had integrated 85% of the acquired NRT portfolio as of Dec'25. Full integration is expected to complete by FY26 end.
- NRT portfolio grew 8% in constant currency terms.
- Launched 10 new products in Europe in Q3 and 31 products in 9MFY26.
- Received European Commission approval and marketing authorisation from UKMHRA for denosumab biosimilar. Denosumab was launched in Germany in Dec'25.

Emerging markets (EM)

- EM growth was largely driven by new product launches across markets, aided by favourable forex.
- Russia grew 51% YoY led by new product launches, higher volumes of existing products, price increase in certain brands and favourable forex.
- Management targets double-digit growth in Russia ahead.
- In Q3FY26, it launched 30 new products across countries, total of 80 for 9MFY26.

PSAI

- Sequential decline in sales was on account of lower volume uptake in API business.
- It filed 31 DMFs globally in Q3FY26, 80 for 9MFY26.

Biosimilar and GLP-1

- In mid-Nov'25, it submitted the response to Pharmaceutical Drugs Directorate in Canada for notice of non-compliance for semaglutide injection. Management expects a revert from the regulator by May'26 and is aiming to launch this product anytime between Feb-May'26.
- Management does not anticipate an inspection of manufacturing plant from Health Canada for generic semaglutide approval.
- Management believes its generic version of semaglutide is substitutable to the innovative product.
- Received marketing authorisation for Semaglutide injection in India from DCGI for diabetes indication. The company has also filed for other indication of this molecule.
- Filed Biologics License Application (BLA) for abatacept biosimilar with the USFDA in Dec'25.
- Abatacept is likely to be filed in Europe in Jul'26 and the launch is targeted by Jul'27.
- Received a CRL from the USFDA for denosumab biosimilar (developed by partner Alvotech). The CRL refers to the observations from a pre-license inspection of Alvotech's Reykjavik manufacturing facility.

- In Sep'25, it received a CRL for rituximab biosimilar BLA, post PAI inspection of biologics facility at Bachupally, Hyderabad. It further received a post- application action letter (PAAL) from the USFDA, in relation to the response submitted.
- Aurigene Pharmaceutical (CDMO business) served as the exclusive API manufacturer for two of 46 Novel Drugs approved by the USFDA in CY25.
- Management expects sales of over USD 100mn from Aurigene in next 2-3 years.
- It plans to launch generic semaglutide in India on 21 Mar'26, Canada by Q1FY26 and Brazil by Jul'26. The company plans to launch the product in ~80 markets.
- DRL has booked capacity of 12mn pens for CY26 and has scope to increase capacity to 50mn in the long term. In-house fill-finish capacity is being developed and is expected to be ready in ~12 months, post which it will also tie up with partners.

Guidance

- Management expects single digit growth in US excluding sales of gRevlimd; it expects double-digit growth in other markets.
- India business is likely to sustain growth of 15-16%.
- Maintains R&D spending guidance at 7-8% of sales for FY26.
- Gross margin of the company is expected between 50-55% in FY26.

Q3FY26 performance

- Revenue of base business grew in double digits (excluding lenalidomide) driven by NRT and forex gains.
- EBITDA margin stood at 24.8% post adjusting for provision for new labour law code (impact of INR 1.17bn).
- Gross margin was impacted by lower sales of Lenalidomide, price erosion in North America and Europe, adverse product mix in PSAI business and a one-time provision related to new labour codes in India (50bps impact). Gross margin stood at 54.1% post adjusting for new labour law code.
- SG&A spend excluding one-off provision stood at 30.2% of sales (60bps impact of provisions).
- R&D was lower due to lower spending on biosimilar, partially offset by one-time provisions (20bps of revenue).
- Net finance cost increased due to higher forex gains.
- ETR in Q3FY26 stood at 22.9%; lower YoY due to favourable jurisdiction mix.
- Operating working capital at the end of Q3FY26 stood at INR 141.4bn.
- Capex in Q3FY26 stood at INR 6.7bn; FCF stood at INR 3.7bn.
- Net cash balance as on 31 Dec'25 stood at INR 36.9bn.

Exhibit 1: Q3FY26 result review

Y/E Mar (INR mn)	Q3FY26	Q3FY25	YoY(%)	Q2FY26	QoQ (%)	9MFY26	9MFY25	YoY(%)
Net Sales	87,268	83,586	4.4	88,051	(0.9)	2,60,771	2,40,475	8.4
Gross Profit	47,242	49,052	(3.7)	48,140	(1.9)	1,44,009	1,43,165	0.6
Gross Margins (%)	54.1	58.7	-455bps	54.7	-54bps	55.2	59.5	-431bps
R&D	5,974	6,658	(10.3)	6,202	(3.7)	18,420	20,122	(8.5)
R&D (%)	6.8	8.0	-112bps	7.0	-20bps	7.1	8.4	-130bps
EBITDA	20,124	22,991	(12.5)	21,295	(5.5)	62,916	66,735	(5.7)
EBITDA Margins (%)	23.1	27.5	-445bps	24.2	-112bps	24.1	27.8	-362bps
Other Income	793	481	64.9	1,185	(33.1)	2,719	2,055	32.3
Interest	(1,168)	20	(5,940.0)	(774)	50.9	(3,512)	(2,372)	48.1
Depreciation	5,215	4,714	10.6	5,051	3.2	15,027	12,490	20.3
Extraordinary expenses	1,441	(4)	-	(147)	-	1,294	1,942	-
PBT	15,429	18,742	(17.7)	18,350	(15.9)	52,826	56,730	(6.9)
Tax	3,533	4,704	(24.9)	4,082	(13.4)	12,566	15,357	(18.2)
Tax Rate (%)	22.9	25.1	-220bps	22.2	65bps	23.8	27.1	-328bps
Minority Interest	(202.0)	(95.0)	112.6	(104.0)	94.2	(388.0)	767.0	(150.6)
PAT	12,098	14,133	(14.4)	14,372	(15.8)	40,648	40,606	0.1
Adj. PAT	13,209	14,130	(6.5)	14,262	(7.4)	41,649	42,062	(1.0)
NPM (%)	13.9	16.9	-305bps	16.3	-246bps	15.6	16.9	-130bps

Source: I-Sec research, Company data

Exhibit 2: Segmental break up

INR mn	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	% YoY	% QoQ
Generics	63,095	61,190	68,857	71,576	73,752	75,364	75,620	78,498	79,113	7.3	0.8
USA	33,492	32,626	38,462	37,281	33,834	35,586	34,123	32,408	29,644	(12.4)	(8.5)
India	11,800	11,265	13,252	13,971	13,464	13,047	14,711	15,780	16,032	19.1	1.6
Europe	4,970	5,208	5,265	5,770	12,096	12,750	12,744	13,762	14,476	19.7	5.2
Russia	5,900	5,000	5,500	6,850	7,000	6,500	7,100	8,750	10,600	51.4	21.1
RoW	4,633	4,891	4,478	5,554	4,958	5,081	4,942	5,460	5,961	20.2	9.2
CIS	2,300	2,200	1,900	2,150	2,400	2,400	2,000	2,338	2,400	-	2.7
API	7,839	8,219	7,657	8,407	8,219	9,563	8,181	9,450	8,018	(2.4)	(15.2)
Proprietary products	1,214	1,420	212	179	1,614	132	1,651	103	137	(91.5)	33.0
Total	72,148	70,829	76,726	80,162	83,585	85,059	85,452	88,051	87,268	4.4	(0.9)
US (USD mn)	401	392	462	445	401	418	400	373	338	(15.7)	(9.4)

Source: I-Sec research, Company data

Exhibit 3: Key growth drivers of domestic business in Q3FY26

Brands (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	MAT Dec'25	MAT Dec'24	YoY (%)
Atarax	716	624	12.0	698	2.5	2,536	2,357	7.6
Ketorol	646	516	20.2	621	4.0	2,389	2,140	11.6
Voveran	644	646	-3.6	623	3.4	2,388	2,405	-0.7
Econorm	508	471	35.4	637	-20.3	2,347	2,188	7.3
Omez	547	525	2.4	537	1.8	2,178	2,228	-2.2
Hexaxim	582	472	-4.9	450	29.4	1,982	1,635	21.2
Venusia	565	473	-13.1	411	37.3	1,814	1,577	15.1
Menactra	484	392	5.6	414	16.9	1,703	1,382	23.2
Zedex	494	459	-1.3	453	8.9	1,678	1,479	13.5
Omez D+	420	362	21.8	441	-4.7	1,625	1,518	7.0


Source: IQVIA

Exhibit 4: Growth profile across key therapies in India

Therapies (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	MAT Dec'25	MAT Dec'24	YoY (%)
Gastro Intestinal	3,032	2,744	10.5	3,190	-4.9	12,173	11,560	5.3
Respiratory	3,206	2,905	10.4	2,930	9.4	10,973	9,867	11.2
Pain / Analgesics	2,269	1,921	18.1	2,176	4.3	8,252	7,588	8.8
Cardiac	1,888	1,666	13.3	1,872	0.8	7,257	6,802	6.7
Vaccines	1,667	1,477	12.9	1,565	6.5	6,296	5,396	16.7
Derma	1,703	1,505	13.2	1,597	6.6	6,205	5,539	12.0
Vitamins/Minerals/Nutrients	1,201	964	24.6	1,292	-7.1	4,735	3,846	23.1
Anti Diabetic	1,071	996	7.5	1,074	-0.3	4,157	4,008	3.7
Neuro/CNS	966	985	-1.9	1,072	-9.8	4,076	4,074	0.1
Stomatologicals	1,032	881	17.2	1,025	0.7	3,864	3,385	14.1


Source: IQVIA

Exhibit 5: Lower gRevlimid sales and price erosion in base biz dampen US growth




Source: I-Sec research, Company data

Exhibit 6: Loss of exclusivity in gRevlimid may drag US growth till FY27E




Source: I-Sec research, Company data

Exhibit 7: India biz growth aided by innovation portfolio, new launch and price hikes




Source: I-Sec research, Company data

Exhibit 8: India biz expected to grow at 11.5% CAGR over FY25-28E




Source: I-Sec research, Company data

Exhibit 9: Revenue growth led by Europe and India




Source: I-Sec research, Company data


Exhibit 10: Revenue to grow at CAGR of 6.7% over FY25-28E




Source: I-Sec research, Company data

Exhibit 11: Gross margin contracted due to lower sales of gRevlimid



Source: I-Sec research, Company data

Exhibit 12: Gross margin may remain at ~55% levels ahead



Source: I-Sec research, Company data

Exhibit 13: EBITDA margin contracted 445bps YoY



Source: I-Sec research, Company data

Exhibit 14: Loss of exclusivity of gRevlimid to curb margins



Source: I-Sec research, Company data

Exhibit 15: Adj. R&D expense declined ~10% YoY to 6.8% of sales



Source: I-Sec research, Company data

Exhibit 16: R&D spend expected to remain at ~7% of sales ahead


Source: I-Sec research, Company data

Exhibit 17: Adj. PAT impacted by weak operating performance


Source: I-Sec research, Company data

Exhibit 18: Adj. PAT likely to decline ~2% over FY25–28E


Source: I-Sec research, Company data

Exhibit 19: Shareholding pattern

%	Jun'25	Sep'25	Dec'25
Promoters	26.6	26.6	26.6
Institutional investors	63.2	63.5	63.8
MFs and others	15.9	15.8	16.6
Insurance Cos	10.6	11.9	14.1
FIIs	36.7	35.8	33.2
Others	10.2	9.9	9.5

Source: Bloomberg, I-Sec research

Exhibit 20: Price chart


Source: Bloomberg, I-Sec research

Financial Summary

Exhibit 21: Profit & Loss

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Net Sales	3,25,535	3,47,745	3,54,215	3,95,248
Operating Expenses	2,38,303	2,64,124	2,74,861	3,02,178
EBITDA	87,232	83,621	79,354	93,070
EBITDA Margin (%)	26.8	24.0	22.4	23.5
Depreciation & Amortization	17,037	20,406	22,068	23,731
EBIT	70,195	63,215	57,286	69,339
Interest expenditure	-	-	-	-
Other Non-operating Income	9,082	8,076	3,901	3,794
Recurring PBT	79,277	71,292	61,187	73,134
Profit / (Loss) from Associates	217	113	124	137
Less: Taxes	19,539	16,546	15,328	18,318
PAT	59,738	54,746	45,859	54,816
Less: Minority Interest	701	(590)	(506)	(605)
Extraordinaries (Net)	(2,710)	(1294)	-	-
Net Income (Reported)	56,544	54,154	46,490	55,558
Net Income (Adjusted)	58,564	55,143	46,490	55,558

Source Company data, I-Sec research

Exhibit 22: Balance sheet

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Total Current Assets	2,50,181	3,05,625	3,42,229	3,98,051
of which cash & cash eqv.	24,602	79,086	1,16,516	1,53,885
Total Current Liabilities & Provisions	91,436	1,07,463	1,09,604	1,21,518
Net Current Assets	1,58,745	1,98,162	2,32,625	2,76,533
Investments	16,079	16,079	16,079	16,079
Net Fixed Assets	96,978	1,01,572	1,04,504	1,05,773
ROU Assets	-	-	-	-
Capital Work-in-Progress	-	-	-	-
Total Intangible Assets	1,09,942	1,09,942	1,09,942	1,09,942
Other assets	940	1,004	1,023	1,141
Deferred Tax Assets	20,146	20,146	20,146	20,146
Total Assets	4,02,830	4,46,906	4,84,319	5,29,614
Liabilities				
Borrowings	46,964	43,964	40,964	37,964
Deferred Tax Liability	14,038	14,038	14,038	14,038
provisions	298	298	298	298
other Liabilities	2,256	2,256	2,256	2,256
Equity Share Capital	834	834	834	834
Reserves & Surplus	3,10,522	3,58,188	3,99,107	4,48,008
Total Net Worth	3,35,496	3,82,572	4,22,985	4,71,280
Minority Interest	3,778	3,778	3,778	3,778
Total Liabilities	4,02,830	4,46,906	4,84,319	5,29,614

Source Company data, I-Sec research

Exhibit 23: Cashflow statement

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Operating Cashflow	46,428	84,537	66,565	67,591
Working Capital Changes	(5,059)	29,054	20,318	8,069
Capital Commitments	(51,021)	(20,565)	(20,565)	(20,565)
Free Cashflow	(4,593)	63,973	46,000	47,026
Other investing cashflow	-	-	-	-
Cashflow from Investing Activities	(51,021)	(20,565)	(20,565)	(20,565)
Issue of Share Capital	193	-	-	-
Interest Cost	-	-	-	-
Inc (Dec) in Borrowings	-	-	-	-
Dividend paid	(6,662)	(6,489)	(5,570)	(6,657)
Others	18,324	(3,000)	(3,000)	(3,000)
Cash flow from Financing Activities	11,855	(9,489)	(8,570)	(9,657)
Chg. in Cash & Bank balance	7,262	54,484	37,430	37,369
Closing cash & balance	14,369	79,086	1,16,516	1,53,885

Source Company data, I-Sec research

Exhibit 24: Key ratios

(Year ending March)

	FY25A	FY26E	FY27E	FY28E
Per Share Data (INR)				
Reported EPS	67.8	64.9	55.7	66.6
Adjusted EPS (Diluted)	70.2	66.1	55.7	66.6
Cash EPS	90.7	90.6	82.2	95.1
Dividend per share (DPS)	8.0	7.8	6.7	8.0
Book Value per share (BV)	402.3	458.7	507.2	565.1
Dividend Payout (%)	11.8	12.0	12.0	12.0
Growth (%)				
Net Sales	16.6	6.8	1.9	11.6
EBITDA	11.5	(4.1)	(5.1)	17.3
EPS (INR)	5.2	(5.9)	(15.7)	19.5
Valuation Ratios (x)				
P/E	17.1	17.8	20.8	17.4
P/CEPS	12.8	12.8	14.1	12.2
P/BV	2.9	2.5	2.3	2.0
EV / EBITDA	12.0	11.8	12.0	9.9
P / Sales	3.3	3.1	3.0	2.7
Dividend Yield (%)	0.7	0.7	0.6	0.7
Operating Ratios				
Gross Profit Margins (%)	58.5	55.2	54.5	55.3
EBITDA Margins (%)	26.8	24.0	22.4	23.5
Effective Tax Rate (%)	24.6	23.2	25.1	25.0
Net Profit Margins (%)	18.4	15.7	12.9	13.9
NWC / Total Assets (%)	-	-	-	-
Net Debt / Equity (x)	(0.1)	(0.2)	(0.3)	(0.3)
Net Debt / EBITDA (x)	(0.3)	(1.0)	(1.5)	(1.6)
Profitability Ratios				
RoCE (%)	16.5	13.0	10.0	11.0
RoE (%)	18.9	15.2	11.4	12.3
RoIC (%)	20.6	16.1	13.6	15.9
Fixed Asset Turnover (x)	4.1	3.8	3.5	3.8
Inventory Turnover Days	86	76	74	77
Receivables Days	109	104	101	105
Payables Days	32	42	42	43

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com and Kadambari_balachandran@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Abdulkader Puranwala, MBA; Nisha Shetty, MBA; Darshil Jain, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report.

SEBI Guidelines for Research Analyst (RA) requires all RAs to disclose terms and conditions pertaining to Research Services to all clients. Please go through the "Mandatory terms and conditions" and "Most Important Terms and Conditions. [\(Link\)](#)

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address :** complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Jeetu Jawrani](#) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
